REG - Beximco Pharmaceut - AGM Notification

Beximco PharmaceuticalsAnnouncement

16/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221116:nRSP4825Ga&default-theme=true

RNS Number : 4825G  Beximco Pharmaceuticals Ltd  16 November 2022

16 November 2022

 

BEXIMCO PHARMACEUTICALS LIMITED

 

AGM Notification

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, today
announces that the forty-sixth Annual General Meeting of Shareholders (AGM) of
Beximco Pharma will be held virtually on Thursday 22 December 2022 at 10.30
a.m. to transact the following business:

 

AGENDA

 

1.   To receive, consider and adopt the Audited Financial Statements of the
Company for the year ended on 30 June 2022 together with reports of the
Auditors and the Directors thereon.

2.   To declare 35% Cash Dividend.

3.   To elect Directors.

4.   To appoint Auditor for the year 2022-2023 and to fix their
remuneration.

5.   To appoint Corporate Governance Compliance Auditor for the year
2022-2023 and to fix their remuneration.

 

 

                         By order of the Board
                         Sd/-
 Dated:15 November 2022  (MOHAMMAD ASAD ULLAH, FCS)

                         Executive Director & Company Secretary

 

 

NOTES:

 

(1) Shareholders whose names appear in the Share Register of the Company or in
the Depository Register on the record date (i.e. 21 November 2022) will be
entitled to attend the AGM and to receive the dividend.

 

(2) A Member entitled to attend and vote at the AGM may appoint a Proxy to
attend and vote in his/her stead. The Proxy Form, duly stamped, must be
deposited at the Registered office of the Company, not later than 48 hours
before the time fixed for the meeting.

 

(3) Annual Report for the year 2021-22 will be sent through e-mail address of
the Shareholders and will be available on the Company website
at: www.beximcopharma.com (http://www.beximcopharma.com/) .

 

(4) Shareholders will join the virtual AGM through the link
https://bxpharma.bdvirtualagm.com. Shareholders will be able to submit their
questions/comments and vote electronically one hour before commencement of the
AGM and also during the AGM. For logging into the system, the Shareholders
need to put their 16-digit Beneficial Owner (BO) ID/Folio Number and other
credential as proof by visiting the said link.

 

(5) We encourage shareholders to login into the system prior to the meeting.
Please allow ample time to login and establish your connectivity. For any IT
related guidance, shareholders may contact vide email: monir@beximco.ne
(mailto:monir@beximco.net) t (mailto:monir@beximco.net)
 or mazibur@beximco.net (mailto:mazibur@beximco.net)  .

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com/)  or enquire to:

Beximco Pharma

 

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, Ext.20080

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

 

Jamal Ahmed Choudhury, Director, Accounts & Finance

Tel: +880 2 58611001, Ext.20022

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Vadim Alexandre / Abigail Wayne

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 5500 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the world.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFVFLSLELIF